



GLOBAL DX VETERINARY IN-VITRO DIAGNOSTICS TECHNOLOGY

Business Opportunity

SIA Group are excited to present a unique opportunity to acquire the intellectual property assets of Global DX Limited (in Administration), an innovative in-vitro diagnostics company specialising in cutting-edge disease testing for animals.

Since its incorporation in 2017, the Global DX has developed a suite of diagnostic antibody tests for the effective and reliable detection of African Swine Fever (ASF), a highly contagious viral disease of pigs with devastating socio-economic consequences across multiple industries worldwide.

These include a fully developed rapid lateral flow test which has been evaluated by a number of world-renowned research institutes and has been proven to significantly outperform other commercially available assays in detecting ASF (sensitivity of 86% compared to 57%).

This test is underpinned by the Company's proprietary Direct Sample Conjugation (DSC) technology, which utilises carbon nanoparticles in place of commonly used metal nanoparticles such as gold colloid, removing the need for preparation of nanoparticle conjugates. The use of DSC technology has several advantages over standard lateral flow tests, including greater sensitivity, reduced production time and costs, greater durability and longer shelf life, along with several advantages over lab-based tests, including rapid deployment and ease of use, which are critical in preventing outbreaks in areas with limited infrastructure.

DSC also has potential to be utilised in other lateral flow tests to diagnose infectious diseases in both humans and animals, in addition to the wider medical diagnostic field, environmental monitoring and food safety industries.

Interested parties are requested to deals specifically with Emily Muir and Emre Turan at SIA Group. Further information including access to a virtual data room can be provided upon execution of an NDA.

It is intended that a sale will be executed at the earliest opportunity and a deadline for expressions of interest has been set for **Tuesday 4th March 2025 at 12pm (GMT)**.



Opportunity Highlights

- Opportunity to access the growing animal diagnostics market and capitalise upon the increasing global focus on animal health and biosecurity
- Transformative DSC technology with the potential to become the gold standard for the next generation of human and animal lateral flow tests
- Significant licensing potential through wider application of DSC technology, including pregnancy and troponin cardiac tests



Assets Available

- Rights to a fully developed ASF antibody test and accompanying DSC technology
- Rights to a near-developed gold colloid ASF antibody test currently undergoing stability testing
- Extensive technical records and lab data
- Organisational knowledge including manufacturing guides, manuals and instructions for use
- Registered trade mark portfolio



Deadline

Expressions of interest must be registered by:
4th March 2025 at 12pm (GMT)

Contact Us



Emily Muir



Emily.Muir@sia-group.co.uk



+44 (0) 7442 936 429



Emre Turan



Emre.Turan@sia-group.co.uk



+44 (0) 7471 996 068